horses will be held in the large anjmal biocontainment facility for three weeks after vaccination at which time serum samples will be obtained for serological analysis and the animals released outside. On day 42, six weeks after immunization, the horses will be returned to the large animal biocontainment facility to be challenged with equine virulent VEE virus.
The animals will be observed two weeks for clinical symptoms, serological analysis, viremia, and then sacrificed for pathological studies. It is anticipated that these studies will be completed in February 1989.
II. VACCINE DEVELOPMENT AND TESTING.

A.
Molecular cloning and genetic analysis of the VEE virus Renome.
The sequence of VEE TRD and TC-83 genomic RNAs were determined by sequencing cDNA clones. The entire nucleotide and deduced amino acid sequences of the VEE TRD genomic RNA are shown in Fig. 1 . Excluding the 5'-m7G cap, the TRD RNA genome was 11,444 nucleotides long with a base composition of 28.2%A, 24.5%C, 25.3%G, and 22.0%U.
In addition to sequence analysis of cDNA clones, three synthetic oligonucleotide primers were used to obtain the 5'-terminal nucleotide sequences from virion RNA templates. Primer extension sequencing of the 5'-termini of the TRD and TC-83 RNAs failed to resolve the 5'-terminal A nucleotide but did confirm the 5'-terminal nucleotides previously determined. TC-83 amd TRD viruses differed in this region with a substitution of A for G at genome nucleotide position 3 in the TC-83 RNA.
Excluding the 5'-prime cap, the 5'-noncoding region of both genomes was 44 nucleotides in length. The putative cleavage sites used to generate the nonstructural polypeptides from the polyprotein precursor were identified by comparing the VEE virus amino acid sequence with the sequences of those for Sindbis (SIN) and Simliki Forest (SF) viruses. The amino acid sequences of the translated nonstructural polyproteins of TRD, SIN, and SF viruses were aligned to provide maximal homology and the sequences of the cognate proteins compared. The nsPl, nsP2, nsP3, and nsP4 polypeptides of VEE TRD virus showed 60%-66%, 57%-58%, 35%-44Z, and 73%-71% sequence identity, respectively. The nsP4 protein was the most highly conserved of the four nonstructural proteins. When the nucleotide sequences of the translated regions of these viruses were aligned, VEE sequences encoding nsPl, nsP2, and nsP4 showed 60%-63%, 57%-58%, 44%-49%, and 65%-63% identity, respectively, with cognate genes of SIN and SF viruses.
The deduced molecular weights of the nsPl, nsP2, and nsP4
poplypeptides were approximately 60, 89, and 68-69 kd, respectively for Fig. 1 ) located six amino acid residues upstream from the carboxylterminus of VEE nsP3 was aligned with the in frame opal codon reported for SIN virus.
The nucleotide and deduced amino acid sequence differences between the genones of VEE TRD and TC-83 virus are summarized in Table 1. TC-83 virus contained a single mutation in the 5'-noncoding region. Additional mutations were noted in the El and E2 glycoproteins, and in the 3'-noncoding region.
B.
Construction of an infectious VEE virus cDNA clone.
Nucleotide sequencing of 11 cDNA clones encoding the entire 42S RNA genomes of both TRD and TC-83 viruses has facilitated the development of a strategy for assembly of a single clone encoding the entire genomes of both viruses (Fig. 2) . Site-specific mutagenesis has been used to create At the 3'-end of the genome, clone pTC-5 which encodes the structural proteins of TC-83 virus, lacks the 3'-terminal 65 nucleotides of the 3'-noncoding region. This clone is currently being modified. To do this, the clone has been inserted into the single-stranded M13 phage and is undergoing modifications to construct the 3'-end of the genome. Once this task has been completed, the middle region, 51-end, and 3'-end clones will be ligated together to form the final full-length cDNA. 
Of the four El glycoprotein epitopes identified for VEE virus, only
Elb and Eld epitopes were detected in recombinant virus-infected cells (Table 1) . Although the Ela and Elc epitopes were detected in VEE TC-83
and TRD virus-infected, acetone-fixed cells, these two epitopes were not evident by FA in recombinant VACC/TC-5A or VACC/TRD-IA infected cells.
D.
Humoral and cell-mediated immune responses to the vaccinia/VEE recombinant.
Murine humoral responses to immunization.
Responses of AJ mice to immunization with recombinant VACC/TC-5A
virus are shown in Prechallange Nt antibody titers in individual animals receiving various doses of recombinant vaccine showed a dose-related response (Table 4) . In all cases, the response to the vaccinia recombinant was lower than that seen in animals which received the TC-83
vaccine. Three mice immunized with the recombinant did not develop Nt antibody and did not survive virus challenge.
AJ mice, immunized with 10 7 PFU of VACC/TC-5A virus, were bled at 18, 33, and 86 days post-immunization to determine the short-term duration of VEE virus immunity (Table 5) . Neutralizing antibody titers indicated that antibody levels elicited by the VACC/TACF5A
vaccine were stable for at least 3 months.
Neutralization antibody titers were determined for both Swiss NIH and C3H mice that received 108 PFU of VACC/TC-5A virus i.d. The recombinant VACC/TC-5A vaccine elicited a weaker immune response in outbred Swiss NIH mice than in the inbred C3H or AJ mice. The VACC/TAC-5A induced tail lesions were also reduced in Swiss NIH mice as compared to either C3H or the AJ mice.
2. Nurine cross-protection studies.
Five individual, high-titered anti-anti-TC-83 or anti-VACC/TC-5A
mouse sera were pooled and tested for their ability to neutralize different antigenic subtypes of VEE virus ( Table 7) .
To determine the level of protection afforded by immunization with recombinant vaccinia virus to aerosol infection, mice were immunized with VACC/TC-5A virus and challenged with virulent TRD virus. The VACC/TC-5A vaccine effectively protected mice against peripheral infection but not intranasal challenge with TRD virus.
However, the TC-83 vaccine protected mice from challenge virus given by either route ( Table 8) IgG and IgM titers are currently being determined.
Helper T-cell responses in vaccinated primates.
Peripheral blood mononuclear cells were obtained from immunized animals. In general, the frequency of antigen primed T-cells in peripheral blood was too low to use this as a lymphocyte source. We subsequently tested lymphocyte populations from axial lymph nodes of vaccinated, challenged animals. The axial lymph node appears to be an adequate lymphocyte source.
Antigen specific helper T-cell activity could be defined by both in vitro proliferation and IL2 production. The antigen specificity of this response was similar to that previously described in the lA3A-5
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